Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026
Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026

Nona Biosciences, a wholly‑owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a multi‑target antibody...

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Fineline Cube Jan 12, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that the National Medical Products...

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Fineline Cube Jan 12, 2026

Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) announced that its subsidiary, Shanghai SPH Zhongxi Pharmaceutical...

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026

The FDA’s Center for Biologics Evaluation and Research (CBER) announced a flexible, lifecycle‑based approach to...

Company Drug

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

Fineline Cube Jan 12, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that DR10624, a long‑acting triple‑target agonist developed by...

Medical Device

Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA

Fineline Cube Jan 12, 2026

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) announced that the New Drug Application (NDA)...

Company

Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity

Fineline Cube Jan 12, 2026

Novartis AG (NYSE: NVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in...

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026

Pierre Fabre Laboratories announced a comprehensive drug discovery collaboration with French AI specialist Iktos to...

Policy / Regulatory

NHSA Launches Personal Healthcare Insurance Cloud Pilot Program

Fineline Cube Jan 12, 2026

China’s National Healthcare Security Administration (NHSA) issued a notice inviting applications for pilot projects to...

Policy / Regulatory

China Expands Medical Insurance Personal Account Pooling Nationwide

Fineline Cube Jan 12, 2026

China’s National Healthcare Security Administration (NHSA) and Ministry of Finance (MoF) jointly issued the “Notice...

Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced it has granted AirNexis Therapeutics exclusive worldwide...

Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026

Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset...

Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that BA6101, its biosimilar version of Amgen’s...

Others

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Fineline Cube Jan 12, 2026

Johnson & Johnson (J&J, NYSE: JNJ) announced a voluntary agreement with the Trump Administration to...

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026

Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced an out‑licensing agreement with Vitamedic Health Nutraceuticals (Brazil),...

Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) is reportedly in advanced negotiations to acquire Revolution Medicines...

Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026

Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced that the conditional New Drug Application (NDA)...

Company Drug

RemeGen’s RC48 Wins Fourth Breakthrough Therapy Designation for Gastric Cancer Combo

Fineline Cube Jan 11, 2026

RemeGen Ltd (SHA: 688331, HKG: 9995) announced that its core product, Disitamab Vedotin (RC48/Aidixi), has...

Company Drug

Merck Initiates Phase 3 Trial for Calderasib + KEYTRUDA QLEX in KRAS G12C NSCLC

Fineline Cube Jan 11, 2026

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) announced the initiation of KANDLELIT‑007, a Phase 3 clinical...

Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced a global collaboration and license agreement...

Posts pagination

1 2 … 607

Recent updates

  • Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform
  • Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study
  • Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution
  • FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development
  • Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Company Drug

Hengrui’s Quadruple Prostate Cancer Combo Wins NMPA IND for Phase 2 Study

Company Drug

Shanghai Pharma Receives NMPA Approval for Myasthenia Gravis Oral Solution

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.